Fig. 4

miR-144-3p may play a bridging role between lnc-PSMA8-1 and mTOR. A: Expression of mTOR in RD and RH30 cells transfected with siRNA (lnc-CEACAM19-1, lnc-VWCE-2, lnc-GPX7-1, or lnc-PSMA8-1) as detected by qRT-PCR. B: Lnc-PSMA8-1 expression in the nuclear and cytoplasmic RNA fractions obtained from RD and RH30 cells as shown by qRT-PCR. C: Predicted miR-144-3p binding sites in lnc-PSMA8-1 sequence and 3’-UTR of GEFT sequence and their induced mutations. D-F: Expression of lnc-PSMA8-1 (D) miR-144-3p (E) and mTOR (F) were detected in RMS samples (n = 20) and normal skeletal muscle samples (n = 10) by qRT-PCR. G-I: Correlation between lnc-PSMA8-1 and miR-144-3p, between miR-144-3p and mTOR, and between lnc-PSMA8-1 and mTOR as analyzed in 20 cases of RMS. J: Expression levels of lnc-PSMA8-1, miR-144-3p and mTOR in RD and RH30 cell lines as determined by qRT-PCR. K: Protein levels of mTOR and p-mTOR in RD and RH30 cell lines as determined by Western blot analysis. All the blots were cropped prior to hybridization with primary antibodies. The original blots are presented in Fig. S2